Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Non Operating Income (2020 - 2025)

Ovid Therapeutics' Non Operating Income history spans 5 years, with the latest figure at $22.0 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 1394.69% year-over-year to $22.0 million; the TTM value through Dec 2025 reached $25.0 million, down 29.4%, while the annual FY2025 figure was $25.0 million, 29.41% down from the prior year.
  • Non Operating Income reached $22.0 million in Q4 2025 per OVID's latest filing, up from $365000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $29.0 million in Q2 2024 to a low of -$780000.0 in Q3 2024.
  • Average Non Operating Income over 4 years is $4.3 million, with a median of $1.2 million recorded in 2022.
  • The largest YoY upside for Non Operating Income was 1546.15% in 2024 against a maximum downside of 200.52% in 2024.
  • A 4-year view of Non Operating Income shows it stood at $668123.0 in 2022, then surged by 329.11% to $2.9 million in 2023, then tumbled by 48.76% to $1.5 million in 2024, then surged by 1394.69% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Non Operating Income are $22.0 million (Q4 2025), $365000.0 (Q3 2025), and $389000.0 (Q2 2025).